New Small-Group CE Opportunities Offer Personalized Virtual Learning

Optimally treating patients with early-stage NSCLC and patients with advanced HER2+ breast cancer requires navigating an ever-changing landscape of diagnostics and treatment options. Staying knowledgeable of the latest science in the treatment of these complex diseases can be challenging for busy professionals, to say the least.

ACCC is offering two new online continuing education (CE) initiatives that leverage small-group learning among clinicians and their peers who have roles in the care and treatment of patients with early-stage NSCLC and patients with advanced HER2+ breast cancer. The small-group courses—limited to 6-15 people—engage learners in both self-paced self-study and collaborative online group tasks aimed at helping participants learn how to optimally manage their patients.

How It Works

Leading this educational initiative are group leaders who are physicians, advanced practice providers (NPs/PAs), and oncology pharmacists with expertise in NSCLC and HER2+ breast cancer. Participants complete a multi-component curriculum that includes self-study materials, live group discussions, and group challenges. Group leaders focus on mentoring and promoting peer-to-peer learning to establish meaningful, small-group interactions that bring context to the material in the self-study units.

Best Practices in Early-Stage NSCLC

In this course, participants who have roles in the care and treatment of patients with early-stage NSCLC will:

• Discuss emerging data from ongoing studies of targeted therapies in the adjuvant setting for early-stage NSCLC
• Review recent clinical data from emerging studies of immunotherapy with checkpoint inhibitors in the neoadjuvant and adjuvant/consolidation setting to optimize survival for patients with early-stage NSCLC
• Assess the role of biomarkers in treatment selection for early-stage NSCLC
• Implement strategies to improve care coordination within the interprofessional cancer care team to improve patient outcomes in early-stage NSCLC

Making Sense of the Evolving Standards of Care for Advanced HER2+ Breast Cancer

In this course, participants who have roles in the care and treatment of patients with advanced HER2+ breast cancer will:

• Optimize outcomes for patients with HER2+ breast cancer who have received prior treatment with anti-HER2 targeted therapies
• Examine solutions for improving care coordination within the interprofessional cancer care team to monitor and manage treatment-related adverse events in patients with HER2+ breast cancer receiving novel targeted therapies
• Review strategies to improve treatment adherence in HER2+ metastatic breast cancer by engaging patients in shared decision-making

Both courses require a time commitment of 2.5 hours and offer CE credit upon completion. Enroll in Best Practices in Early-Stage NSCLC and Making Sense of the Evolving Standards of Care for Advanced HER2+ Breast Cancer by Nov. 8, 2021, to participate. If you would like to learn more about participating or serving as a group leader, please contact Rukiya Wongus, ACCC Program Manager.